Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Biden admin announces framework to potentially seize drug patents in bid to cut consumer costs
06:52pm, Thursday, 07'th Dec 2023
The Biden administration floated the possibility of seizing the patents for high-priced medications from pharmaceutical companies in a move to lower drug prices. The White House put out a fact sheet
My Top 10 High Dividend Yield Companies For December 2023
06:00pm, Thursday, 07'th Dec 2023
High dividend yield companies can provide investors with several benefits, such as the generation of income and the reduction of portfolio volatility. Furthermore, the companies' continuous dividend p
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
05:00am, Thursday, 07'th Dec 2023
These companies all have solid histories of dividend increases and are making future dividend payments a priority. You can likely count on them to grow your passive income from year to year.
Pfizer (PFE) Declines More Than Market: Some Information for Investors
06:47pm, Wednesday, 06'th Dec 2023
In the most recent trading session, Pfizer (PFE) closed at $28.79, indicating a -1.03% shift from the previous trading day.
Pfizer CEO slams presidents of elite colleges over ‘despicable' antisemitism
06:30pm, Wednesday, 06'th Dec 2023
Pfizer CEO Albert Bourla criticized the "despicable" testimony of three elite university presidents who were "hiding behind calls for 'context'" before deeming such rhetoric impermissible.
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
12:48pm, Wednesday, 06'th Dec 2023
Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patien
Diamonds in the Rough: 3 Undervalued Stocks with Huge Upside
01:56pm, Tuesday, 05'th Dec 2023
In the stock market, value is often found in places that other investors might miss. So, the first main quality of hidden gem stocks is their undervaluation.
Pfizer's Obesity Pill Disappointed. Biotech Rivals Are Rubbing Their Hands.
12:14pm, Tuesday, 05'th Dec 2023
Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.
7 Compelling Stocks to Buy That are Sitting at 52-Week Lows
08:41am, Tuesday, 05'th Dec 2023
In arguably most circumstances, when you see stocks at 52-week lows, you should avoid them. Based on prevailing market theory, equity valuations culminate from the most recent publicly available infor
Johnson & Johnson Vs. Pfizer: Better Pharma Stock?
12:55am, Tuesday, 05'th Dec 2023
Johnson & Johnson demonstrates better R&D efficiency and has a larger patent portfolio compared to Pfizer. JNJ's product pipeline in the Pharmaceutical segment has more late-stage developments, suppor
Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024
06:04pm, Monday, 04'th Dec 2023
Pfizer has experienced a total return loss of nearly -40% so far in 2023, largely due to downshifts in demand for COVID-19 vaccines and antiviral products. Shareholders faced additional challenges, in
Ozempic vs. Mounjaro:: Battle of the bulge
10:16am, Monday, 04'th Dec 2023
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Nov
Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
06:46am, Monday, 04'th Dec 2023
The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.
Is Pfizer Stock a Buy Now?
05:00am, Sunday, 03'rd Dec 2023
Pfizer's sales are on the decline as coronavirus-related products slip and other blockbusters face competition. But the company has planned for this moment and is in the middle of an impressive streak
Pfizer: Between Hope, Despair, And A 5.7% Yield
02:31am, Sunday, 03'rd Dec 2023
Pfizer has underperformed the S&P 500, healthcare stocks, and high-yield stocks since 2013. The company's weight-loss pill has faced setbacks and is not competitive with leading drugs from other pharm
